Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by LVW Advisors LLC

LVW Advisors LLC increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,320 shares of the medical equipment provider’s stock after acquiring an additional 119 shares during the quarter. LVW Advisors LLC’s holdings in Intuitive Surgical were worth $587,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after buying an additional 272,741 shares in the last quarter. Capital World Investors raised its stake in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares during the last quarter. Edgewood Management LLC lifted its holdings in Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after buying an additional 374,667 shares during the period. Finally, Fisher Asset Management LLC raised its stake in Intuitive Surgical by 2.0% during the 4th quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after buying an additional 88,977 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Citigroup boosted their price objective on Intuitive Surgical from $462.00 to $512.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Barclays upped their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Morgan Stanley increased their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Finally, BTIG Research increased their price objective on shares of Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $442.30.

Insider Buying and Selling

In related news, Director Craig H. Barratt sold 2,496 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $402.89, for a total value of $1,005,613.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, Director Craig H. Barratt sold 2,496 shares of Intuitive Surgical stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $402.89, for a total transaction of $1,005,613.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mark Brosius sold 175 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $387.22, for a total transaction of $67,763.50. Following the transaction, the senior vice president now owns 533 shares in the company, valued at approximately $206,388.26. The disclosure for this sale can be found here. Insiders have sold 15,307 shares of company stock worth $6,623,651 over the last ninety days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Stock Down 0.2 %

ISRG stock traded down $1.10 on Tuesday, reaching $464.43. 134,987 shares of the company’s stock were exchanged, compared to its average volume of 1,556,126. The stock has a fifty day moving average of $438.40 and a 200-day moving average of $405.13. The firm has a market cap of $164.73 billion, a PE ratio of 84.43, a P/E/G ratio of 4.97 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $470.49.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.